Nonalcoholic steatohepatitis (NASH) is a progressive liver disease that poses a growing global health concern. As its prevalence rises, the demand for effective treatments is driving significant investment in drug development. Although no FDA-approved NASH therapeutics are currently available, several promising candidates are progressing through clinical trials. Researchers and pharmaceutical...